Loading
Obstructive Sleep Apnea / Maridebart cafraglutide · Phase 3 Trial
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized controlled trial registered at ClinicalTrials.gov comparing maridebart cafraglutide to placebo in adults with obstructive sleep apnea not on PAP therapy. The trial is currently recruiting and has not yet posted results; the registry record contains only the planned design, endpoints, and population.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Obstructive Sleep Apnea; age from 18 Years; to 99 Years. Intervention: Maridebart Cafraglutide. Compared with: Placebo — Placebo Comparator. n = 250. 57 sites across 11 countries.
This is a Phase 3 randomized controlled trial registered at ClinicalTrials.gov comparing maridebart cafraglutide to placebo in adults with obstructive sleep apnea not on PAP therapy. The trial is currently recruiting and has not yet posted results; the registry record contains only the planned design, endpoints, and population.
This is a registry record only; no efficacy or safety results have been reported. Effect sizes, p-values, confidence intervals, and adverse event data are not available.
The source did not state who this applies to in practice.
This is a registered but actively recruiting Phase 3 trial with no reported results; the registry record describes planned design and endpoints only, not outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07226765). This is a study registration, not published results. Lead sponsor: Amgen. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 250 participants (ESTIMATED). Conditions: Obstructive Sleep Apnea. Interventions: DRUG: Maridebart cafraglutide; DRUG: Placebo. Primary outcome measures: Change in Apnea-hypopnea Index (AHI) from baseline at Week 52 , At Week 52. Brief summary: This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are not on PAP therapy and are living with overweight or obesity.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.